KPF_Examining the Utility of In Vitro Bioactivity as a Protective Point of Departure: A Case Study_APCRA
The files and .R scripts here are provided to aid in understanding and reproduction of the analyses in the submitted paper, "Examining the Utility of In Vitro Bioactivity as a Protective Point of Departure: A Case Study."
The scripts in the .R folder reference source files in the other folders.
This dataset is associated with the following publication:
Friedman, K., M. Gagne, L. Loo, P. Karamertzanis, T. Netzeva, T. Sobanski, J. Franzosa, A. Richard, R. Lougee, A. Gissi, J.J. Lee, M. Angrish, J. Dorne, S. Foster, K. Raffaele, T. Bahadori, M. Gwinn, J. Lambert, M. Whelan, M. Rasenberg, T. Barton-Maclaren, and R. Thomas. Utility of In Vitro Bioactivity as a Lower Bound Estimate of In Vivo Adverse Effect Levels and in Risk-Based Prioritization. TOXICOLOGICAL SCIENCES. Society of Toxicology, RESTON, VA, 173(1): 202-225, (2020).
Resources
1 resource available
-
https://github.com/USEPA/-Examining-the-Utility-of-In-Vitro-Bioactivity
FILE
Find Related Datasets
Search by Tags
Click any tag below to search for similar datasets
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| bureauCode |
[ "020:00" ] |
| contactPoint |
{ "fn": "Richard Judson", "hasEmail": "mailto:judson.richard@epa.gov" } |
| description | The files and .R scripts here are provided to aid in understanding and reproduction of the analyses in the submitted paper, "Examining the Utility of In Vitro Bioactivity as a Protective Point of Departure: A Case Study." The scripts in the .R folder reference source files in the other folders. This dataset is associated with the following publication: Friedman, K., M. Gagne, L. Loo, P. Karamertzanis, T. Netzeva, T. Sobanski, J. Franzosa, A. Richard, R. Lougee, A. Gissi, J.J. Lee, M. Angrish, J. Dorne, S. Foster, K. Raffaele, T. Bahadori, M. Gwinn, J. Lambert, M. Whelan, M. Rasenberg, T. Barton-Maclaren, and R. Thomas. Utility of In Vitro Bioactivity as a Lower Bound Estimate of In Vivo Adverse Effect Levels and in Risk-Based Prioritization. TOXICOLOGICAL SCIENCES. Society of Toxicology, RESTON, VA, 173(1): 202-225, (2020). |
| distribution |
[ { "title": "https://github.com/USEPA/-Examining-the-Utility-of-In-Vitro-Bioactivity", "accessURL": "https://github.com/USEPA/-Examining-the-Utility-of-In-Vitro-Bioactivity" } ] |
| identifier | https://doi.org/10.23719/1503823 |
| keyword |
[ "ACToR", "Threshold of Toxicological Concern (TTC)", "high-throughput screening", "high-throughput toxicokinetics", "new approach methodologies", "point of departure (POD)" ] |
| license | https://pasteur.epa.gov/license/sciencehub-license.html |
| modified | 2019-06-04 |
| programCode |
[ "020:095" ] |
| publisher |
{ "name": "U.S. EPA Office of Research and Development (ORD)", "subOrganizationOf": { "name": "U.S. Environmental Protection Agency", "subOrganizationOf": { "name": "U.S. Government" } } } |
| references |
[ "https://doi.org/10.1093/toxsci/kfz201" ] |
| rights |
null
|
| title | KPF_Examining the Utility of In Vitro Bioactivity as a Protective Point of Departure: A Case Study_APCRA |
